Logo image of ATNX

ATHENEX INC (ATNX) Stock Fundamental Analysis

NASDAQ:ATNX - Nasdaq - US04685N2027 - Common Stock - Currency: USD

0.2031  -0.06 (-23.39%)

After market: 0.1873 -0.02 (-7.78%)

Fundamental Rating

2

Overall ATNX gets a fundamental rating of 2 out of 10. We evaluated ATNX against 566 industry peers in the Biotechnology industry. Both the profitability and financial health of ATNX have multiple concerns. While showing a medium growth rate, ATNX is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ATNX had negative earnings in the past year.
In the past year ATNX has reported a negative cash flow from operations.
ATNX had negative earnings in each of the past 5 years.
In the past 5 years ATNX always reported negative operating cash flow.
ATNX Yearly Net Income VS EBIT VS OCF VS FCFATNX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 -50M -100M -150M

1.2 Ratios

The profitability ratios for ATNX are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ATNX Yearly ROA, ROE, ROICATNX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 0 500 1K 1.5K

1.3 Margins

ATNX has a better Gross Margin (25.25%) than 75.24% of its industry peers.
In the last couple of years the Gross Margin of ATNX has declined.
The Profit Margin and Operating Margin are not available for ATNX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 25.25%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.96%
GM growth 5Y-5.22%
ATNX Yearly Profit, Operating, Gross MarginsATNX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 -100 -200 -300 -400

More info and screens

0

2. Health

2.1 Basic Checks

ATNX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ATNX has more shares outstanding
ATNX has a worse debt/assets ratio than last year.
ATNX Yearly Shares OutstandingATNX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M
ATNX Yearly Total Debt VS Total AssetsATNX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of -7.74, we must say that ATNX is in the distress zone and has some risk of bankruptcy.
ATNX has a worse Altman-Z score (-7.74) than 72.36% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -7.74
ROIC/WACCN/A
WACC6.5%
ATNX Yearly LT Debt VS Equity VS FCFATNX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 100M -100M

2.3 Liquidity

A Current Ratio of 1.09 indicates that ATNX should not have too much problems paying its short term obligations.
ATNX's Current ratio of 1.09 is on the low side compared to the rest of the industry. ATNX is outperformed by 86.42% of its industry peers.
A Quick Ratio of 0.72 indicates that ATNX may have some problems paying its short term obligations.
The Quick ratio of ATNX (0.72) is worse than 90.42% of its industry peers.
Industry RankSector Rank
Current Ratio 1.09
Quick Ratio 0.72
ATNX Yearly Current Assets VS Current LiabilitesATNX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M 200M 250M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 20.08% over the past year.
Looking at the last year, ATNX shows a very strong growth in Revenue. The Revenue has grown by 35.70%.
Measured over the past years, ATNX shows a very strong growth in Revenue. The Revenue has been growing by 22.03% on average per year.
EPS 1Y (TTM)20.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.13%
Revenue 1Y (TTM)35.7%
Revenue growth 3Y0.53%
Revenue growth 5Y22.03%
Sales Q2Q%110.87%

3.2 Future

Based on estimates for the next years, ATNX will show a very strong growth in Earnings Per Share. The EPS will grow by 36.27% on average per year.
The Revenue is expected to decrease by -15.37% on average over the next years. This is quite bad
EPS Next Y70.35%
EPS Next 2Y36.27%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-30.28%
Revenue Next 2Y-15.37%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
ATNX Yearly Revenue VS EstimatesATNX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M
ATNX Yearly EPS VS EstimatesATNX Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 -10 -20 -30 -40

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ATNX. In the last year negative earnings were reported.
Also next year ATNX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ATNX Price Earnings VS Forward Price EarningsATNX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ATNX Per share dataATNX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10

4.3 Compensation for Growth

ATNX's earnings are expected to grow with 36.27% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.27%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ATNX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ATHENEX INC

NASDAQ:ATNX (5/24/2023, 8:00:00 PM)

After market: 0.1873 -0.02 (-7.78%)

0.2031

-0.06 (-23.39%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08 2023-05-08/bmo
Earnings (Next)07-26 2023-07-26/bmo
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners17.09%
Ins Owner Change0%
Market Cap1.76M
Analysts77.78
Price Target2.3 (1032.45%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-66.79%
Min EPS beat(2)-142.07%
Max EPS beat(2)8.5%
EPS beat(4)2
Avg EPS beat(4)-49.79%
Min EPS beat(4)-142.07%
Max EPS beat(4)17.44%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-28.91%
Min Revenue beat(2)-71.48%
Max Revenue beat(2)13.65%
Revenue beat(4)3
Avg Revenue beat(4)11.2%
Min Revenue beat(4)-71.48%
Max Revenue beat(4)90.23%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)3.84%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-23.78%
EPS NY rev (1m)0%
EPS NY rev (3m)-1093.78%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-33.93%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.01
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-15.88
EYN/A
EPS(NY)-4.71
Fwd EYN/A
FCF(TTM)-8.9
FCFYN/A
OCF(TTM)-8.66
OCFYN/A
SpS15.23
BVpS-0.75
TBVpS-9.07
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 25.25%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.96%
GM growth 5Y-5.22%
F-Score2
Asset Turnover0.65
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 88.72%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.09
Quick Ratio 0.72
Altman-Z -7.74
F-Score2
WACC6.5%
ROIC/WACCN/A
Cap/Depr(3y)157.31%
Cap/Depr(5y)208.3%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)20.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.13%
EPS Next Y70.35%
EPS Next 2Y36.27%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)35.7%
Revenue growth 3Y0.53%
Revenue growth 5Y22.03%
Sales Q2Q%110.87%
Revenue Next Year-30.28%
Revenue Next 2Y-15.37%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y19.4%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y46.84%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y47.31%
OCF growth 3YN/A
OCF growth 5YN/A